Repligen Corp. Stock
Price
Target price
€122.70
€122.70
-1.390%
-1.75
-1.390%
€180.11
17.09.24 / Tradegate
WKN: 870980 / Symbol: RGEN / Name: Repligen Corp / Stock / Pharmaceuticals / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Repligen Corp. Stock
We can see a decrease in the price for Repligen Corp.. Compared to yesterday it has lost -€1.750 (-1.390%).
With 14 Buy predictions and not the single Sell prediction the community is currently very high on Repligen Corp..
With a target price of 180 € there is a positive potential of 46.7% for Repligen Corp. compared to the current price of 122.7 €.
So far the community has only identified positive things for Repligen Corp. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Repligen Corp. in the next few years
Pros
?
S********** s********
?
B****
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Repligen Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Repligen Corp. | -1.390% | -5.724% | -8.364% | -19.488% | -26.790% | -53.114% | 67.600% |
| Opko Health Inc. | 0.760% | 7.130% | 8.625% | -2.492% | 5.024% | -54.053% | -23.916% |
| Catalent Inc. | -0.530% | 0.240% | 0.742% | 23.012% | 31.820% | -53.581% | 18.078% |
| Amicus Therapeutics Inc. | 1.020% | -1.000% | -3.883% | -18.852% | -25.000% | 5.882% | 14.266% |
Comments
Repligen Co. (NASDAQ: RGEN) had its price target raised by analysts at JPMorgan Chase & Co. from $190.00 to $200.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) had its price target lowered by analysts at UBS Group AG from $205.00 to $185.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $190.00 price target on the stock.
Show more
Ratings data for RGEN provided by MarketBeat